Loading
Latest filing published 06 Mar 2023 for Quince Therapeutics, Inc., €1,726. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Ted Monohon, listed as senior executive, appears in our data through filings on IRulya Therapeutics Inc. shares, published by SEC (Form 4). In total, 5 filings cover trades dated from 3 March 2022 to 6 March 2023.
No open-market purchase appears, only 1 sale worth €1,726. Besides market trades, the filings include 4 share grants. So far in 2023, the count stands at no purchases and 1 sale.
The latest filing, published on 6 March 2023, reports an open-market sale of €1,726 in IRulya Therapeutics Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations